Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC).

E Edmond Rafie (Research Center of the Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada) S Sebastian Hunter (Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada) M Myriam Benlaifaoui (Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada) C Corentin Richard J Julie Malo (Centre de recherche du CHUM (Canada), Montreal, QC, Canada) C Catherine Lehoux-Dubois (Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada) M Marjorie Drolet (Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada) L Lisa Derosa (Gustave Roussy) W Wiam Belkaid (CHUM, Montreal, QC, Canada) N Normand Blais (Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada) M Marie Florescu (Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada) M Mustapha Tehfe A Antoine Desilets (Memorial Sloan Kettering Cancer Center, New York, NY) M Meriem Messaoudene V Valérie Marcil (Université de Montréal, Montreal, QC, Canada) B Bertrand Routy A Arielle Elkrief

Abstract

2567 Background: The gut microbiome is a modulator of ICI activity. Diet is among the most important factors influencing the gut microbiome. We previously showed that high fiber was not associated with outcome in NSCLC, in contrast to melanoma. However, the impact of dietary patterns and specific nutrients on ICI outcomes in NSCLC is unknown. Methods: At the CHUM Microbiome Centre, a nutritionist prospectively collected dietary history using a validated DHQ-II survey from 147 patients (pts) with advanced NSCLC treated with ICI alone or in combination with chemotherapy. Global dietary patterns and a systematic screen of 72 macro- and micronutrients (cut-offs defined by median) were examined for their association with progression-free survival (PFS) in univariable and multivariable cox-regression analyses. Associations between diet and immune-related adverse events (irAE) were examined. In 69 pts, shotgun metagenomic sequencing (WMS) was performed on fecal samples to determine differential abundance of bacteria using linear discriminant analyses, heatmaps, and MaAsLin2. Results: Median age was 68, 46% were male. Median follow-up was 13 months. Total caloric intake adjusted for basal metabolic rate (Mifflin-St Jeor equation using BMI and activity level) was not associated with PFS (p = 0.3). In univariable analyses, the following nutrients were associated with improved PFS: vitamin K (HR 0.62, p = 0.03), fat (HR 0.65, p = 0.04); while the following were associated with inferior PFS: starch (HR 1.61, p = 0.03), carbohydrates (HR 1.56, p = 0.04), sucrose (HR 1.62, p = 0.03), and iron (HR 1.7, p = 0.016). In a multivariable analysis examining all macro- and micronutrients and adjusting for BMI, vitamin K intake was significantly associated with improved PFS (HR 0.60, 95% CI 0.37, 0.97, p = 0.04). Fat-based diets such as keto-like diet (high fat, low starch) was associated with improved PFS in univariable (HR, 0.47, p = 0.008) and multivariable analyses (HR 0.37, 95%CI 0.2, 0.68, p = 0.001). Compared to high starch diet, western diet (high fat, high starch) was associated with increased risk of any grade irAE (24% vs 54%, respectively, p = 0.01). WMS analyses revealed biologically relevant signals; fat-based diets were associated with enrichment of favorable commensal bacteria such as Ruminococcus lactaris , Butyricimonas faecihominis , Lachnospiraceae spp, with low fat associated with deleterious Veillonella atypica . Starch-based diets were associated with high Prevotella spp. Sucrose-enriched diets were enriched with Candidatus saccharibacteria , a known sucrose-fermenting bacteria. Conclusions: Our results demonstrate the importance of diet on ICI outcomes in NSCLC and WMS results suggest this is mediated by the gut microbiome. Diet is a modifiable lifestyle factor which may be targeted to improve ICI activity, meriting study in a randomized trial.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 2567-2567
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (17)

E

Edmond Rafie

Research Center of the Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada

S

Sebastian Hunter

Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada

M

Myriam Benlaifaoui

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada

C

Corentin Richard

J

Julie Malo

Centre de recherche du CHUM (Canada), Montreal, QC, Canada

C

Catherine Lehoux-Dubois

Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada

M

Marjorie Drolet

Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada

L

Lisa Derosa

Gustave Roussy

W

Wiam Belkaid

CHUM, Montreal, QC, Canada

N

Normand Blais

Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada

M

Marie Florescu

Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada

M

Mustapha Tehfe

A

Antoine Desilets

Memorial Sloan Kettering Cancer Center, New York, NY

M

Meriem Messaoudene

V

Valérie Marcil

Université de Montréal, Montreal, QC, Canada

B

Bertrand Routy

A

Arielle Elkrief